Demand Prediction for 2015

Projected Shift in Disease Profile from 2005 to 2015

Growth of Drugs and Pharmaceuticals Industry

PAT/Income(%)
16 14 12 10 8 6 4 2 0 2009-2010 2010-2011 2011-2012(Forcast) PAT/Income(%)

Export of Pharmaceutical Product from India

USD billion
12 10 8 6 4 2 0 USD billion

Import of Pharmaceutical Product to India

Major Indian Pharma Industry Players:

Government Projected Growth of Drug and Pharmaceutical Industy

Trend in Revenue Growth of MnCs in the Indian Market

Trend in US formulation on Indian Companies

Details of ANDA filing by Leading Indian Companies

Expected Market Size of Branded Product Expires in US Year

Porters 5 Forces Analysis

SWOT Analysis: STRENGTH

WEAKNESS Low technology level of Capital Goods of this section. Non-availability of major intermediaries

Availability of Cheap raw material(most economical raw material in the world after China)

Availability of professional manpower with good technical expertise Low cost of production. Large pool of installed capacities Efficient technologies for large number of Generics. Large pool of skilled technical manpower. Increasing liberalization of government policies.

for bulk drugs. Lack of experience to exploit efficiently the new patent regime. Very low key R&D. Less Awareness on IPR. Very low level of Biotechnology in India and also for New Drug Discovery Systems. Low level of strategic planning for future and also for technology forecasting.

OPPORTUNITY

THREAT

Very lucrative high profit making market with high chances of growth Increased awareness amongst people about Health Prodcuts Aging of the world population. Growing incomes. Growing attention for health. New diagnoses and new social diseases. Spreading prophylactic approaches. Saturation point of market is far away. New therapy approaches. New delivery systems. Spreading attitude for soft medication (OTC drugs). Spreading use of Generic Drugs. Globalization Easier international trading. New markets are opening.

Entry of other foreign competitors in the Indian market Containment of rising health-care cost. High Cost of discovering new products and fewer discoveries. Stricter registration procedures. High entry cost in newer markets. High cost of sales and marketing. Competition, particularly from generic products. More potential new drugs and more efficient therapies. Switching over form process patent to product patent.